Effect of N-acetylcysteine on Malondyaldehyde Content After Iron Treatment in Chronic Kidney Disease Stage 5D Patients

Abstract

Objective: This study was performed to evaluate and assess the influence of N-acetylcysteine (NAC) on malondialdehyde (MDA) levels as a biomarker of oxidative stress in chronic kidney disease (CKD) stage 5D (hemodialyzed) patients after parenteral iron therapy. Materials and Methods: This was a randomized, open-label, parallel-group trial comparing oxidative stress induced by intravenous (IV) administration of 100 mg of iron sucrose (control group) with an additional IV administration of 5 g NAC. At hemodialysis (HD) sessions pre- and post-plasma MDA levels were measured. Eighteen patients were enrolled, including 9 as controls and 9 in the treatment group. Results: In the control group, plasma MDA level increased from 3.71μM to 13.89μM (p=0.008), whereas in the treatment group, the level increased from 4.48μM to 7.89μM (p=0.059). The difference between the groups was also significantly different (p=0.015). Conclusions: It appears that NAC has the ability to decrease MDA level as a biomarker of oxidative stress caused by iron treatment in CKD patients.